Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Biologics in Plaque Psoriasis

Streamlined Drug Class Review        
Draft recommendations posted for stakeholder feedback: September 21, 2023            
End of feedback period: October 5, 2023,   

Recommendations and Reasons (draft) 

Responses to Questions from the Drug Programs (draft) 

Updated Recommendations for Biologics in Plaque Psoriasis (draft) 

Submit Feedback

 

rivaroxaban (N/A)

Therapeutic Area: Venous thromboembolic events (VTE)         
Draft recommendations posted for stakeholder feedback: September 21, 2023             
End of feedback period: October 6, 2023,         
 

Draft Recommendation and Reasons

Draft Responses to Questions from the Drug Programs

Submit Feedback

 

setmelanotide (Imcivree)

Therapeutic Area: Bardet-Biedl syndrome          
Draft recommendations posted for stakeholder feedback: September 14, 2023             
End of feedback period: September 28, 2023             
Draft Recommendation

Submit Feedback

 

dupilumab (Dupixent)

Therapeutic Area: Atopic dermatitis, pediatrics            
Draft recommendations posted for stakeholder feedback: September 14, 2023             
End of feedback period: September 28, 2023             
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Emergency Department Overcrowding in Canada: An Update                                         
End of feedback period: September, 2023

Statements of Interest

NovoTTF-200A ( Optune )                           
End of feedback period: January, 2024

Statements of Interest

2024 Watch List: Care for Children and Youth With Medical Complexity                          
End of feedback period: January, 2024

Statements of Interest

Therapeutic Area
Therapeutic Area: Crohn’s disease and Ulcerative Colitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Seizures associated with Tuberous Sclerosis Complex (TSC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Endogenous Cushing’s syndrome
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Locally advanced or metastatic NSCLC (first line)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Dravet Syndrome (DS)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Lennox-Gastaut Syndrome (LGS)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Relapsed or refractory multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: